Medical/Pharmaceuticals
ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research
NEWARK, Del., April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been continuously rolling out a series of innovative organoid-related products. At a range of significant international events, including the 2024 International Organoid Summit, the Alzheimer's Research UK Conferenc...
2024-04-10 21:00
1564
3Shape Charts Sustainable Course with Release of Comprehensive Sustainability Report 2023
Highlighted in the company's latest report, 3Shape plans to inspire sustainability awareness in the dental industry through its new 5-year sustainability plan. COPENHAGEN, Denmark, April 10, 2024 /PRNewswire/ -- 3Shape, the global innovator in digital dentistry, is proud to unveil its 2023 Susta...
2024-04-10 18:29
1540
Leading the Way: Nicklaus Children's Hospital Awarded Global Healthcare Accreditation with Excellence for Pediatric Medical Travel Services
MIAMI, April 10, 2024 /PRNewswire/ -- Nicklaus Children's Hospital in Miami, Florida, proudly announces its achievement of Global Healthcare Accreditation (GHA) with Excellence for Medical Travel Services. This is Nicklaus Children's Hospital's second GHA Accreditation with Excellence, a distinct...
2024-04-10 18:00
1647
Tsingke Showcases Cutting-Edge Biologics Solutions at Biologics 2024
BEIJING and PARIS, April 10, 2024 /PRNewswire/ -- On March 15th, Biologics 2024 successfully concluded inLondon, with 650 pharmaceutical, biotechnology, and academic representatives and over 50 exhibitors engaging in high-level discussions on the latest innovations in biologics discovery and deve...
2024-04-10 14:19
1282
ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research
TOKYO, April 10, 2024 /PRNewswire/ -- Starting in 2023, ACROBiosystems has been launching a continuous stream of innovative organoid-related products. Displaying their advancements at key global forums including the 2024 International Organoid Summit, Alzheimer's Research UK Conference 2024, and ...
2024-04-10 14:05
1964
R&D Progress: Enrollment of Subjects in Phase III Clinical Trial for Inhaled Aerosol Drug in Children by Kexing Biopharm
SHENZHEN, China, April 10, 2024 /PRNewswire/ -- Recently, Kexing Biopharm (688136.SH) announced that the Phase III clinical trial of Human Interferon α1b Inhalation Solution developed by its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., had completed the enrollment of first p...
2024-04-10 11:41
2330
Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR
* The dose-escalation results of JSKN003 was reported at this AACR conference. * JSKN003 exhibited a favorable tolerability, safety profile and encouraging preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors. The ORR in patients with HER2+ BC was 100...
2024-04-10 08:40
2053
Neoss Integrate Australia 2024 - Integrate. Educate. Celebrate
QUEENSLAND, Australia, April 9, 2024 /PRNewswire/ -- This summer, Neoss Australia &New Zealand are celebrating 20 years of Intelligent Simplicity and invites the dental community to join us for an exceptional scientific program with over 21 speakers across two days. Taking place on the Gold Coas...
2024-04-09 23:24
1633
The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements
SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held fromMarch 29th toApril 1st, 2024, in Shenzhen, China. The TICSSO was initiated by Prof. Xinghua Pan (Southern Medical University), Prof. Fuchou Tang (Peking Un...
2024-04-09 23:14
1762
BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3
SHANGHAI, April 9, 2024 /PRNewswire/ -- BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for a Phase 1 study of BC2027. BC2027, which is BioCity's second first-in-class antibody drug conjugate (...
2024-04-09 22:10
1632
Datasea Announces Intent of its CEO to Purchase Up $3,000,000 of its Common Stock in Open Market Purchases
BEIJING, April 9, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and Ch...
2024-04-09 22:00
3727
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
GAITHERSBURG, Md., April 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...
2024-04-09 20:00
1479
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
BEIJING, SHANGHAI, and SAN DIEGO, April 9, 2024 /PRNewswire/ -- Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivat...
2024-04-09 19:59
1342
GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at ...
2024-04-09 19:00
1672
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentatio...
2024-04-09 19:00
1380
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system
AUSTIN, Texas, April 9, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center became the first in the nation to use a novel pulsed field ablation (PFA) system to treat patients with paroxysmal and persistent atrial fibrillation, a...
2024-04-09 18:15
1584
Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA
* Sales double in the USA, order intake increases by over 150 percent * More than 50 percent increase in order intake in EMEA * Business Area Technology & Services' sales grow by almost 25 percent * Further improvement in profitability * Exyte CEO Büchele: "Our follow-the-client strategy ...
2024-04-09 17:52
1958
Waters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors
News Summary: * New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and eliminate up to 40% of common errorsi. * Featuring MaxPeak™ High Performance Surface (HPS) Technology, the new system minimizes unwanted anal...
2024-04-09 14:00
1911
Transcenta Announces Collaboration with Agilent to Develop a Claudin18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial
PRINCETON, N.J. and SUZHOU, China, April 9, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, and Agilen...
2024-04-09 09:18
1851
Abbisko Completed All Patient Enrollment for The Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib
SHANGHAI, April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time), Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) STUDY, for evaluating the efficacy and safety of pimicotinib in patient...
2024-04-09 08:30
1439
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
